bupropion

Summary

Summary: A unicyclic, aminoketone antidepressant. The mechanism of its therapeutic actions is not well understood, but it does appear to block dopamine uptake. The hydrochloride is available as an aid to smoking cessation treatment.

Top Publications

  1. Sheng L, Tang Y, Jiang Z, Yao C, Gao J, Xu G, et al. Sustained-release bupropion for smoking cessation in a Chinese sample: a double-blind, placebo-controlled, randomized trial. Nicotine Tob Res. 2013;15:320-5 pubmed publisher
    b>Bupropion is a first-line pharmacological aid for smoking cessation; however, no clinical trials have been conducted in a Chinese population...
  2. Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomäki T. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. Curr Med Res Opin. 2010;26:549-60 pubmed publisher
    To assess the cost effectiveness of varenicline compared with bupropion or unaided cessation for smoking cessation in Finnish adult smokers...
  3. Cinciripini P, Robinson J, Karam Hage M, Minnix J, Lam C, Versace F, et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry. 2013;70:522-33 pubmed publisher
    Given the actions of varenicline tartrate and bupropion hydrochloride sustained-release (SR) on neurobiological targets related to affect and reward, it is thought that the modulation of nicotine withdrawal symptoms may contribute to ..
  4. Apovian C, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21:935-43 pubmed publisher
    To examine the effects of naltrexone/bupropion (NB) combination therapy on weight and weight-related risk factors in overweight and obese participants...
  5. Tsoi D, Porwal M, Webster A. Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2010;196:346-53 pubmed publisher
    The benefits and harms of bupropion as an aid for smoking cessation in schizophrenia remain uncertain. To summarise the current evidence for efficacy and safety of bupropion as treatment for nicotine dependence in schizophrenia...
  6. Sicras Mainar A, Navarro Artieda R, Díaz Cerezo S, Martí Sánchez B, Sanz de Burgoa V. [Abstinence rates with varenicline compared to bupropion and nicotine replacement therapy for quitting smoking in primary care]. Aten Primaria. 2011;43:482-9 pubmed publisher
    The objective of this study was to estimate the continuous abstinence rates of varenicline, bupropion and nicotine replacement therapy (NRT) in smoking cessation in 2 Primary Care (PC) External Support Units...
  7. Makowski C, Gwinn K, Hurren K. Naltrexone/bupropion: an investigational combination for weight loss and maintenance. Obes Facts. 2011;4:489-94 pubmed publisher
    Naltrexone/bupropion is an investigational combination for weight loss and maintenance in patients who are obese or have a BMI ? 27 kg/m(2) with comorbid diabetes, hypertension or hyperlipidemia...
  8. Faseru B, Nollen N, Mayo M, Krebill R, Choi W, Benowitz N, et al. Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial. Addict Behav. 2013;38:1796-803 pubmed publisher
    ..of successful cessation in African American (AA) light smokers treated within a placebo-controlled trial of bupropion. We analyzed data from a randomized, double-blind, placebo-controlled trial of bupropion and health education ..
  9. Schindler C, Gilman J, Panlilio L, McCann D, Goldberg S. Comparison of the effects of methamphetamine, bupropion, and methylphenidate on the self-administration of methamphetamine by rhesus monkeys. Exp Clin Psychopharmacol. 2011;19:1-10 pubmed publisher
    ..Like pretreatment with methamphetamine, pretreatment with bupropion (3.2 mg/kg) decreased methamphetamine self-administration but did not affect responding for food...

More Information

Publications61

  1. Planer D, Lev I, Elitzur Y, Sharon N, Ouzan E, Pugatsch T, et al. Bupropion for smoking cessation in patients with acute coronary syndrome. Arch Intern Med. 2011;171:1055-60 pubmed publisher
    ..Nevertheless, over two-thirds of patients continue to smoke after an acute myocardial infarction. Bupropion hydrochloride has proven efficacy as a smoking cessation aid, but data regarding its safety and efficacy in ACS ..
  2. Wilcox C, Oskooilar N, Erickson J, Billes S, Katz B, Tollefson G, et al. An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addict Behav. 2010;35:229-34 pubmed publisher
    A combination of sustained release (SR) naltrexone (32 mg/day) and bupropion SR (360 mg/day) plus behavioral counseling was evaluated for the treatment of smoking cessation and mitigation of nicotine withdrawal and weight gain...
  3. Bayard M, Bailey B, Acharya D, Ambreen F, Duggal S, Kaur T, et al. Bupropion and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med. 2011;24:422-8 pubmed publisher
    ..Most antidepressants exacerbate symptoms; however, correlational studies have noted symptom improvement with bupropion. The purpose of the current study was to examine whether, in a controlled study, bupropion would improve the ..
  4. Halpern B, Faria A, Halpern A. Bupropion/naltrexone fixed-dose combination for the treatment of obesity. Drugs Today (Barc). 2011;47:575-81 pubmed publisher
    The combination of bupropion and naltrexone is one of the most promising new possibilities for the treatment of obesity in an era of increasing prevalence of this disease and decreasing options for its pharmacological management...
  5. Mills E, Thorlund K, Eapen S, Wu P, Prochaska J. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation. 2014;129:28-41 pubmed publisher
    ..We aimed to examine whether the 3 licensed smoking cessation therapies-nicotine replacement therapy, bupropion, and varenicline-were associated with an increased risk of cardiovascular disease events using a network meta-..
  6. Carroll F, Muresan A, Blough B, Navarro H, Mascarella S, Eaton J, et al. Synthesis of 2-(substituted phenyl)-3,5,5-trimethylmorpholine analogues and their effects on monoamine uptake, nicotinic acetylcholine receptor function, and behavioral effects of nicotine. J Med Chem. 2011;54:1441-8 pubmed publisher
    Toward development of smoking cessation aids superior to bupropion (2), we describe synthesis of 2-(substituted phenyl)-3,5,5-trimethylmorpholine analogues 5a-5h and their effects on inhibition of dopamine, norepinephrine, and serotonin ..
  7. Jesse C, Wilhelm E, Nogueira C. Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion. Psychopharmacology (Berl). 2010;212:513-22 pubmed publisher
    ..study determined the effect of bis selenide and conventional antidepressants (fluoxetine, amitriptyline, and bupropion) on neuropathic pain using mechanical allodynic and on depressive-like behavior...
  8. Surovik J, Riddel C, Chon S. A case of bupropion-induced Stevens-Johnson syndrome with acute psoriatic exacerbation. J Drugs Dermatol. 2010;9:1010-2 pubmed
    b>Bupropion is a very popular medication prescribed to millions of patients globally for depression (Wellbutrin, GlaxoSmithKline, Research Triangle Park, NC) as well as an aid in smoking cessation (Zyban, GlaxoSmithKline, Research Triangle ..
  9. Pandhare A, Hamouda A, Staggs B, Aggarwal S, Duddempudi P, Lever J, et al. Bupropion binds to two sites in the Torpedo nicotinic acetylcholine receptor transmembrane domain: a photoaffinity labeling study with the bupropion analogue [(125)I]-SADU-3-72. Biochemistry. 2012;51:2425-35 pubmed publisher
    b>Bupropion, a clinically used antidepressant and smoking-cessation drug, acts as a noncompetitive antagonist of nicotinic acetylcholine receptors (nAChRs)...
  10. Hemauer S, Patrikeeva S, Wang X, Abdelrahman D, Hankins G, Ahmed M, et al. Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. Biochem Pharmacol. 2010;80:1080-6 pubmed publisher
    Cigarette smoking during pregnancy is a preventable risk factor associated with maternal and fetal complications. Bupropion is an antidepressant used successfully for smoking cessation in non-pregnant patients...
  11. Qin W, Zhang W, Liu Z, Chen X, Tan Z, Hu D, et al. Rapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men. Br J Clin Pharmacol. 2012;74:999-1004 pubmed publisher
    This study aimed to investigate the effect of metamizole on bupropion hydroxylation related to different CYP2B6 genotype groups in healthy volunteers...
  12. Jafarinia M, Mohammadi M, Modabbernia A, Ashrafi M, Khajavi D, Tabrizi M, et al. Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. Hum Psychopharmacol. 2012;27:411-8 pubmed publisher
    To compare the safety and efficacy of bupropion with methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder (ADHD)...
  13. DellaGioia N, Devine L, Pittman B, Hannestad J. Bupropion pre-treatment of endotoxin-induced depressive symptoms. Brain Behav Immun. 2013;31:197-204 pubmed publisher
    ..This is a follow-up study to determine whether LPS-induced symptoms could be reduced by pre-treatment with bupropion, a norepinephrine and dopamine reuptake inhibitor...
  14. Cahill K, Stead L, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2012;:CD006103 pubmed publisher
    ..We also included comparisons with bupropion and nicotine patches where available...
  15. Mills E, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert J. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med. 2012;44:588-97 pubmed publisher
    ..of NRT for increasing smoking abstinence rates compared to standard-dose NRT patch, varenicline, and bupropion on smoking abstinence...
  16. Kotlyar M, Drone D, Thuras P, Hatsukami D, Brauer L, Adson D, et al. Effect of stress and bupropion on craving, withdrawal symptoms, and mood in smokers. Nicotine Tob Res. 2011;13:492-7 pubmed publisher
    ..The purpose of this study was to determine the effect of bupropion (an agent known to increase smoking cessation rates) on the craving, withdrawal, and mood response to stressful ..
  17. Kalman D, Herz L, MONTI P, Kahler C, Mooney M, Rodrigues S, et al. Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: results from a randomized, double-blind, placebo-controlled study. Drug Alcohol Depend. 2011;118:111-8 pubmed publisher
    ..this study was to compare the efficacy of smoking cessation treatment using a combination of nicotine patch and bupropion vs. nicotine patch and placebo bupropion...
  18. Katsiki N, Hatzitolios A, Mikhailidis D. Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?. Ann Med. 2011;43:249-58 pubmed publisher
    ..This review considers the results of phase III clinical trials with naltrexone sustained-release (SR) + bupropion SR combination therapy in obese patients with or without type 2 diabetes mellitus...
  19. O Byrne P, Williams R, Walsh J, Gilmer J. The aqueous stability of bupropion. J Pharm Biomed Anal. 2010;53:376-81 pubmed publisher
    In this study the aqueous stability of bupropion was determined and the pH-degradation profile was obtained...
  20. Chen Y, Liu H, Liu L, Nguyen K, Jones E, Fretland A. The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19. Xenobiotica. 2010;40:536-46 pubmed publisher
    The involvement of cytochrome P450 2B6 (CYP2B6) to the in vitro and in vivo metabolism of bupropion has been well studied...
  21. Greenway F, Fujioka K, Plodkowski R, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595-605 pubmed publisher
    ..Combination treatment with sustained-release naltrexone and bupropion was developed to produce complementary actions in CNS pathways regulating bodyweight...
  22. Levine M, Perkins K, Kalarchian M, Cheng Y, Houck P, Slane J, et al. Bupropion and cognitive behavioral therapy for weight-concerned women smokers. Arch Intern Med. 2010;170:543-50 pubmed publisher
    ..We sought to determine if the combination of CONCERNS and bupropion therapy would enhance abstinence for weight-concerned women smokers...
  23. Billes S, Greenway F. Combination therapy with naltrexone and bupropion for obesity. Expert Opin Pharmacother. 2011;12:1813-26 pubmed publisher
    ..Naltrexone/bupropion combination therapy was developed by using technological advances that have improved our understanding of how ..
  24. Santamaria A, Arias H. Neurochemical and behavioral effects elicited by bupropion and diethylpropion in rats. Behav Brain Res. 2010;211:132-9 pubmed publisher
    This study is an attempt to demonstrate whether bupropion (BP) and diethylpropion (DEP) exert their pharmacological actions by similar neurochemical mechanisms in the dorsal striatum...
  25. Arias H, Feuerbach D, Targowska Duda K, Aggarwal S, Lapinsky D, Jozwiak K. Structural and functional interaction of (±)-2-(N-tert-butylamino)-3'-iodo-4'-azidopropiophenone, a photoreactive bupropion derivative, with nicotinic acetylcholine receptors. Neurochem Int. 2012;61:1433-41 pubmed publisher
    ..of (±)-2-(N-tert-butylamino)-3'-iodo-4'-azidopropiophenone [(±)-SADU-3-72], a photoreactive analog of bupropion (BP), were characterized at different muscle nicotinic acetylcholine receptors (AChRs) by functional and ..
  26. Viviani R, Abler B, Seeringer A, Stingl J. Effect of paroxetine and bupropion on human resting brain perfusion: an arterial spin labeling study. Neuroimage. 2012;61:773-9 pubmed publisher
    ..spin labeling (ASL) was used to quantify the effect of seven days of administration of paroxetine (20 mg), bupropion (150 mg) on cerebral blood flow levels at rest in a double-blind, placebo-controlled crossover design in N=21 ..
  27. Kitamura Y, Yagi T, Kitagawa K, Shinomiya K, Kawasaki H, Asanuma M, et al. Effects of bupropion on the forced swim test and release of dopamine in the nucleus accumbens in ACTH-treated rats. Naunyn Schmiedebergs Arch Pharmacol. 2010;382:151-8 pubmed publisher
    The dopamine reuptake inhibitor bupropion has clinically been proven to improve depression and treatment-resistant depression...
  28. Egerton A, Shotbolt J, Stokes P, Hirani E, Ahmad R, Lappin J, et al. Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: an [11C]raclopride PET study. Neuroimage. 2010;50:260-6 pubmed publisher
    b>Bupropion is an effective medication in treating addiction and is widely used as an aid to smoking cessation...
  29. Schnoll R, Martinez E, Tatum K, Weber D, Kuzla N, Glass M, et al. A bupropion smoking cessation clinical trial for cancer patients. Cancer Causes Control. 2010;21:811-20 pubmed publisher
    ..This double-blind placebo-controlled trial randomized 246 cancer patients to 9 weeks of placebo or bupropion, stratifying by pre-treatment depression symptoms...
  30. Han D, Hwang J, Renshaw P. Bupropion sustained release treatment decreases craving for video games and cue-induced brain activity in patients with Internet video game addiction. Exp Clin Psychopharmacol. 2010;18:297-304 pubmed publisher
    b>Bupropion has been used in the treatment of patients with substance dependence based on its weak inhibition of dopamine and norepinephrine reuptake...
  31. Chung J, Cho J, Lim H, Kim J, Yu K, Lim K, et al. Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. Drug Metab Dispos. 2011;39:92-7 pubmed publisher
    ..NR1I2) in Korean individuals (n = 83) and the effects of NR1I2 genotypes on rifampin-mediated induction of bupropion hydroxylation...
  32. Smith S, Fujioka K, Gupta A, Billes S, Burns C, Kim D, et al. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes Obes Metab. 2013;15:863-6 pubmed publisher
    The effects of combination naltrexone/bupropion therapy on body composition and visceral adipose tissue (VAT) mass were examined in a subset (n?=?107) of obese subjects from a Phase 2 trial that compared the efficacy and safety of ..
  33. Leventhal A, David S, Brightman M, Strong D, McGeary J, Brown R, et al. Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. Pharmacogenomics J. 2012;12:86-92 pubmed publisher
    ..ancestry taking part in a double-blind placebo-controlled randomized trial of 12 weeks of treatment with bupropion along with counseling for smoking cessation were genotyped for a variable number of tandem repeats polymorphism ..
  34. Wadden T, Foreyt J, Foster G, Hill J, Klein S, O Neil P, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19:110-20 pubmed publisher
    This 56-week, randomized, placebo-controlled trial examined the efficacy and safety of naltrexone plus bupropion as an adjunct to intensive behavior modification (BMOD). A total of 793 participants (BMI = 36.5 ± 4...
  35. Pasternak B, Svanström H, Hviid A. Use of varenicline versus bupropion and risk of psychiatric adverse events. Addiction. 2013;108:1336-43 pubmed publisher
    ..whether varenicline use was associated with increased risk of psychiatric adverse events, compared with bupropion, another drug used for smoking cessation...
  36. Socała K, Nieoczym D, Wyska E, Poleszak E, Wlaz P. Influence of sildenafil on the antidepressant activity of bupropion and venlafaxine in the forced swim test in mice. Pharmacol Biochem Behav. 2012;103:273-8 pubmed publisher
    ..Sildenafil, a selective PDE5 inhibitor, was shown to abolish the anti-immobility effects of bupropion, venlafaxine and s-citalopram in mice...
  37. Culbertson C, Bramen J, Cohen M, London E, Olmstead R, Gan J, et al. Effect of bupropion treatment on brain activation induced by cigarette-related cues in smokers. Arch Gen Psychiatry. 2011;68:505-15 pubmed publisher
    ..b>Bupropion hydrochloride treatment reduces cue-induced craving in cigarette smokers; however, the mechanism by which ..
  38. McCann D, Li S. A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial. CNS Neurosci Ther. 2012;18:414-8 pubmed publisher
    A multisite, double-blind, placebo-controlled trial of bupropion for methamphetamine dependence was reanalyzed using a novel, nonbinary method of evaluating success and failure...
  39. King D, Paciga S, Pickering E, Benowitz N, Bierut L, Conti D, et al. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology. 2012;37:641-50 pubmed publisher
    ..In the first pharmacogenetic investigation of the efficacy of varenicline and bupropion, we examined whether genes important in the pharmacodynamics and pharmacokinetics of these drugs and nicotine ..
  40. Moore T, Furberg C, Glenmullen J, Maltsberger J, Singh S. Suicidal behavior and depression in smoking cessation treatments. PLoS ONE. 2011;6:e27016 pubmed publisher
    Two treatments for smoking cessation--varenicline and bupropion--carry Boxed Warnings from the U.S. Food and Drug Administration (FDA) about suicidal/self-injurious behavior and depression...
  41. Perkins K, Karelitz J, Jao N, Stratton E. Possible reinforcement enhancing effects of bupropion during initial smoking abstinence. Nicotine Tob Res. 2013;15:1141-5 pubmed publisher
    ..Recent rodent research suggests that bupropion may reverse this attenuation, perhaps helping explain its efficacy in aiding cessation...
  42. Eisenberg M, Grandi S, Gervais A, O Loughlin J, Paradis G, Rinfret S, et al. Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial. J Am Coll Cardiol. 2013;61:524-32 pubmed publisher
    The purpose of this study was to examine smoking cessation rates among smokers with AMI to determine whether bupropion, started in-hospital, is safe and can improve cessation rates at 1 year...
  43. Javelot T, Javelot H, Baratta A, Weiner L, Messaoudi M, Lemoine P. [Acute psychotic disorders related to bupropion: review of the literature]. Encephale. 2010;36:461-71 pubmed publisher
    b>Bupropion, or amfebutamone, is an atypical antidepressant also used during tobacco cessation. From a structural standpoint, it resembles amphetamine drugs with psychostimulant effects, and endogenous monoamines...
  44. Brensilver M, Heinzerling K, Swanson A, Shoptaw S. A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: suggested guidelines for treatment discontinuation/augmentation. Drug Alcohol Depend. 2012;125:169-72 pubmed publisher
    Two clinical trials have shown efficacy for bupropion in treating methamphetamine (MA) dependence among those with moderate baseline MA use...
  45. Hudson A, Lalies M, Silverstone P. Venlafaxine enhances the effect of bupropion on extracellular dopamine in rat frontal cortex. Can J Physiol Pharmacol. 2012;90:803-9 pubmed publisher
    ..Another antidepressant, bupropion, acts to inhibit dopamine (DA) and NA reuptake and is commonly co-administered with other antidepressants to ..
  46. Maneeton N, Maneeton B, Srisurapanont M, Martin S. Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials. Psychiatry Clin Neurosci. 2011;65:611-7 pubmed publisher
    The aim of this study was to systematically review the efficacy, acceptability and tolerability of bupropion in comparison to placebo. Only randomized-controlled trials were included in the meta-analysis...
  47. Załuska M, Dyduch A. Bupropion in the treatment of depression in Parkinson's disease. Int Psychogeriatr. 2011;23:325-7 pubmed publisher
    ..Her motor abilities improved on levodopa and the depression improved after a trial of bupropion, following unsuccessful treatment with other antidepressants...
  48. Barczyński B, Buszewicz G, Łuszczki J, Bańka K, Tutaj K, Mróz T, et al. Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. Eur J Pharmacol. 2011;650:550-5 pubmed publisher
    Experimental evidence indicates that bupropion hydrochloride, an antidepressant and a first-line smoking cessation aid, exerts dose-dependently anticonvulsant and convulsant effects...
  49. Kim H, Bae S, Park S, Shim E, Kim H, Shon J, et al. Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects. Br J Clin Pharmacol. 2010;70:126-31 pubmed publisher
    ..5 and 5.9 microM, respectively. Bupropion undergoes metabolic transformation to the active metabolite, 4-hydroxybupropion, primarily via CYP2B6 both in ..
  50. Meyer T, Taylor L, Xie S, Graham D, Mosholder A, Williams J, et al. Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System. Addiction. 2013;108:203-10 pubmed publisher
    ..Results were similar after 60 days of follow-up. There does not appear to be an increase in neuropsychiatric hospitalizations with varenicline compared with nicotine replacement therapy patch over 30 or 60 days after drug initiation. ..
  51. Abler B, Seeringer A, Hartmann A, Gron G, Metzger C, Walter M, et al. Neural correlates of antidepressant-related sexual dysfunction: a placebo-controlled fMRI study on healthy males under subchronic paroxetine and bupropion. Neuropsychopharmacology. 2011;36:1837-47 pubmed publisher
    ..b>Bupropion, a norepinephrine and dopamine reuptake inhibitor, is recommended as an alternative treatment without adverse ..
  52. Safarinejad M. Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study. J Psychopharmacol. 2011;25:370-8 pubmed publisher
    ..This trial examined the efficacy and safety of adjunctive bupropion in the treatment of SSRI-induced female sexual dysfunction...